BioRem Past Earnings Performance

Past criteria checks 3/6

BioRem has been growing earnings at an average annual rate of 40.1%, while the Commercial Services industry saw earnings growing at 6.7% annually. Revenues have been growing at an average rate of 10.4% per year. BioRem's return on equity is 25.6%, and it has net margins of 7.6%.

Key information

40.10%

Earnings growth rate

51.81%

EPS growth rate

Commercial Services Industry Growth7.30%
Revenue growth rate10.44%
Return on equity25.60%
Net Margin7.55%
Last Earnings Update31 Mar 2025

Recent past performance updates

Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

Apr 19
Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

Recent updates

Is BioRem (CVE:BRM) Using Too Much Debt?

Feb 13
Is BioRem (CVE:BRM) Using Too Much Debt?

Investors Continue Waiting On Sidelines For BioRem Inc. (CVE:BRM)

Oct 11
Investors Continue Waiting On Sidelines For BioRem Inc. (CVE:BRM)

Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

Apr 19
Solid Earnings May Not Tell The Whole Story For BioRem (CVE:BRM)

BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs Reward

Apr 12
BioRem Inc. (CVE:BRM) Soars 35% But It's A Story Of Risk Vs Reward

BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Jan 25
BioRem (CVE:BRM) Has A Pretty Healthy Balance Sheet

Is BioRem (CVE:BRM) Using Too Much Debt?

Aug 26
Is BioRem (CVE:BRM) Using Too Much Debt?

Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

Mar 23
Here's Why BioRem (CVE:BRM) Can Manage Its Debt Responsibly

BioRem (CVE:BRM) Could Easily Take On More Debt

Aug 25
BioRem (CVE:BRM) Could Easily Take On More Debt

These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

May 20
These 4 Measures Indicate That BIOREM (CVE:BRM) Is Using Debt Reasonably Well

Here's What's Concerning About BIOREM's (CVE:BRM) Returns On Capital

Jan 26
Here's What's Concerning About BIOREM's (CVE:BRM) Returns On Capital

Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay Cheque

Nov 23
Key Things To Understand About BIOREM's (CVE:BRM) CEO Pay Cheque

Revenue & Expenses Breakdown

How BioRem makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSXV:BRM Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2536350
31 Dec 2437360
30 Sep 2440560
30 Jun 2431440
31 Mar 2428340
31 Dec 2325240
30 Sep 2324150
30 Jun 2326160
31 Mar 2328160
31 Dec 2229260
30 Sep 2229250
30 Jun 2226240
31 Mar 2225240
31 Dec 2124140
30 Sep 2122150
30 Jun 2121140
31 Mar 2121150
31 Dec 2024250
30 Sep 2021-150
30 Jun 2023-160
31 Mar 2023-160
31 Dec 1921-160
30 Sep 1927560
30 Jun 1925550
31 Mar 1925550
31 Dec 1824550
30 Sep 1822140
30 Jun 1823240
31 Mar 1823140
31 Dec 1723240
30 Sep 1719140
30 Jun 1718040
31 Mar 1715040
31 Dec 1616130
30 Sep 1614130
30 Jun 1615130
31 Mar 1616240
31 Dec 1517240
30 Sep 1518240
30 Jun 1516141
31 Mar 1513-131
31 Dec 1411-231
30 Sep 1412-131
30 Jun 1415-141

Quality Earnings: BRM has high quality earnings.

Growing Profit Margin: BRM's current net profit margins (7.6%) are lower than last year (11%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BRM has become profitable over the past 5 years, growing earnings by 40.1% per year.

Accelerating Growth: BRM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BRM had negative earnings growth (-11.2%) over the past year, making it difficult to compare to the Commercial Services industry average (11.6%).


Return on Equity

High ROE: BRM's Return on Equity (25.6%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/29 22:48
End of Day Share Price 2025/05/29 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioRem Inc. is covered by 0 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.